Keyphrases
Liver Transplantation
100%
Liver Transplant Recipients
41%
Hepatitis C Virus
29%
Sustained Virological Response
26%
Chronic Hepatitis C
19%
Hepatocellular Carcinoma
18%
Hepatitis C Virus Infection
16%
Cirrhosis
13%
Ribavirin
11%
Hepatitis C
10%
Tacrolimus
10%
Patient Survival
10%
Liver Biopsy
10%
Hepatitis B Immunoglobulin
9%
Cirrhotic Patients
9%
AIDS/HIV
9%
Daclatasvir
9%
Orthotopic Liver Transplantation
8%
Co-infected Patients
8%
Antiviral Treatment
8%
Hepatitis C Virus Recurrence
8%
Direct-acting Antivirals
7%
Hepatitis B Virus Recurrence
7%
Hepatocellular Carcinoma Recurrence
7%
Sofosbuvir
7%
Transplantation
7%
Waiting List
7%
Acute Liver Failure
6%
Pretransplant
6%
HIV Patients
6%
Liver
6%
Pegylated Interferon
6%
Donor Age
6%
Adult Patients
6%
High-resolution
6%
Prospective Cohort Study
6%
Pediatric Liver Transplantation
6%
Antiretroviral Therapy
6%
Renal Disease
5%
Post-liver Transplantation
5%
Hepatitis B Virus DNA
5%
Genotype 1
5%
Hepatitis C Virus RNA
5%
Hepatitis C Virus Genotypes
5%
Acute Phase
5%
Hepatitis B Virus
5%
Graft Survival
5%
Immunosuppression
5%
Medicine and Dentistry
Liver Transplantation
69%
Liver Graft
40%
Hepatitis C
30%
Hepatitis C Virus
29%
Recurrent Disease
26%
Hepatocellular Carcinoma
16%
Transplantation
14%
Infection
14%
Liver Cirrhosis
13%
Human Immunodeficiency Virus
13%
Antiviral Therapy
12%
Ribavirin
12%
Antivirus Agent
9%
Cohort Analysis
8%
Peginterferon
7%
Pediatrics
7%
Hepatitis B
7%
Acute Liver Failure
6%
Daclatasvir
6%
Graft Survival
6%
Sofosbuvir
6%
Prospective Cohort Study
6%
Allograft
5%
Liver Biopsy
5%
Liver Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis C
32%
Recurrent Disease
30%
Hepatitis C Virus
27%
Infection
18%
Antivirus Agent
15%
Liver Cell Carcinoma
13%
Ribavirin
12%
Tacrolimus
12%
Liver Cirrhosis
11%
Hepatitis B Virus
11%
Hepatitis B
10%
Liver Disease
9%
Daclatasvir
9%
HIV
9%
Cohort Study
8%
Peginterferon
7%
Sofosbuvir
7%
Antiviral Therapy
6%